Xencor, Inc. (XNCR)
USD 8.56
(-4.09%)
USD 8.56
(-4.09%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 952.69 Million USD | 12.58% |
| 2022 | 846.26 Million USD | 0.96% |
| 2021 | 838.21 Million USD | 19.19% |
| 2020 | 703.24 Million USD | 4.92% |
| 2019 | 670.25 Million USD | 16.22% |
| 2018 | 576.73 Million USD | 47.84% |
| 2017 | 390.1 Million USD | -8.97% |
| 2016 | 428.56 Million USD | 107.13% |
| 2015 | 206.91 Million USD | 205.07% |
| 2014 | 67.82 Million USD | -22.32% |
| 2013 | 87.31 Million USD | 648.91% |
| 2012 | 11.65 Million USD | -47.89% |
| 2011 | 22.37 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 826.16 Million USD | -6.57% |
| 2024 Q1 | 884.25 Million USD | -7.18% |
| 2023 Q4 | 952.69 Million USD | 22.39% |
| 2023 FY | 952.69 Million USD | 12.58% |
| 2023 Q2 | 778.12 Million USD | -3.15% |
| 2023 Q1 | 803.41 Million USD | -5.06% |
| 2023 Q3 | 778.43 Million USD | 0.04% |
| 2022 Q2 | 851.32 Million USD | -0.77% |
| 2022 Q4 | 846.26 Million USD | 1.32% |
| 2022 FY | 846.26 Million USD | 0.96% |
| 2022 Q1 | 857.92 Million USD | 2.35% |
| 2022 Q3 | 835.26 Million USD | -1.89% |
| 2021 Q4 | 838.21 Million USD | 20.21% |
| 2021 Q1 | 692.73 Million USD | -1.49% |
| 2021 Q2 | 695.6 Million USD | 0.41% |
| 2021 Q3 | 697.26 Million USD | 0.24% |
| 2021 FY | 838.21 Million USD | 19.19% |
| 2020 Q2 | 644.72 Million USD | -3.33% |
| 2020 Q3 | 646.34 Million USD | 0.25% |
| 2020 Q4 | 703.24 Million USD | 8.8% |
| 2020 FY | 703.24 Million USD | 4.92% |
| 2020 Q1 | 666.96 Million USD | -0.49% |
| 2019 Q1 | 697 Million USD | 20.85% |
| 2019 FY | 670.25 Million USD | 16.22% |
| 2019 Q2 | 684.75 Million USD | -1.76% |
| 2019 Q4 | 670.25 Million USD | -2.33% |
| 2019 Q3 | 686.24 Million USD | 0.22% |
| 2018 Q3 | 585.58 Million USD | -0.99% |
| 2018 Q4 | 576.73 Million USD | -1.51% |
| 2018 FY | 576.73 Million USD | 47.84% |
| 2018 Q1 | 612.27 Million USD | 56.95% |
| 2018 Q2 | 591.45 Million USD | -3.4% |
| 2017 Q2 | 416.16 Million USD | -0.51% |
| 2017 Q3 | 398.25 Million USD | -4.3% |
| 2017 Q4 | 390.1 Million USD | -2.05% |
| 2017 FY | 390.1 Million USD | -8.97% |
| 2017 Q1 | 418.3 Million USD | -2.39% |
| 2016 FY | 428.56 Million USD | 107.13% |
| 2016 Q2 | 334.28 Million USD | 72.34% |
| 2016 Q1 | 193.96 Million USD | -6.26% |
| 2016 Q4 | 428.56 Million USD | 33.04% |
| 2016 Q3 | 322.13 Million USD | -3.63% |
| 2015 Q4 | 206.91 Million USD | -2.16% |
| 2015 FY | 206.91 Million USD | 205.07% |
| 2015 Q3 | 211.48 Million USD | 22.55% |
| 2015 Q2 | 172.56 Million USD | -3.4% |
| 2015 Q1 | 178.63 Million USD | 163.39% |
| 2014 Q3 | 70.86 Million USD | -7.2% |
| 2014 Q1 | 82.49 Million USD | -5.52% |
| 2014 Q4 | 67.82 Million USD | -4.29% |
| 2014 FY | 67.82 Million USD | -22.32% |
| 2014 Q2 | 76.36 Million USD | -7.43% |
| 2013 Q2 | 21.33 Million USD | 0.0% |
| 2013 Q3 | 20.2 Million USD | -5.27% |
| 2013 Q1 | - USD | -100.0% |
| 2013 FY | 87.31 Million USD | 648.91% |
| 2013 Q4 | 87.31 Million USD | 332.12% |
| 2012 Q4 | 11.65 Million USD | 0.0% |
| 2012 FY | 11.65 Million USD | -47.89% |
| 2011 FY | 22.37 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | 35.979% |
| Alkermes plc | 2.13 Billion USD | 55.403% |
| Agenus Inc. | 313.91 Million USD | -203.489% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 75.125% |
| Aptorum Group Limited | 20.64 Million USD | -4515.735% |
| Ardelyx, Inc. | 297.57 Million USD | -220.148% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | -24.445% |
| Bicycle Therapeutics plc | 595.34 Million USD | -60.024% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -1192.627% |
| ChromaDex Corporation | 54.96 Million USD | -1633.302% |
| Chimerix, Inc. | 212.77 Million USD | -347.748% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -3269.69% |
| Caribou Biosciences, Inc. | 440.96 Million USD | -116.046% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 57.27% |
| Precision BioSciences, Inc. | 159.78 Million USD | -496.249% |
| Dyadic International, Inc. | 8.21 Million USD | -11491.004% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -2901.55% |
| Fortress Biotech, Inc. | 167.52 Million USD | -468.683% |
| Lantern Pharma Inc. | 43.64 Million USD | -2082.69% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -490.498% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -6467.279% |
| Incyte Corporation | 6.78 Billion USD | 85.953% |
| IO Biotech, Inc. | 150.71 Million USD | -532.102% |
| Jaguar Health, Inc. | 50.76 Million USD | -1776.745% |
| Novavax, Inc. | 1.85 Billion USD | 48.651% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -150.44% |
| Opthea Limited | 188.79 Million USD | -404.627% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | -14.36% |
| ContextLogic Inc. | 423 Million USD | -125.223% |
| MiMedx Group, Inc. | 239.04 Million USD | -298.538% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -448.388% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -18328.377% |
| NextCure, Inc. | 129.41 Million USD | -636.136% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -1665.945% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -2493.841% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -2849.42% |
| Vaxcyte, Inc. | 1.4 Billion USD | 32.333% |
| PDS Biotechnology Corporation | 59.39 Million USD | -1504.126% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | -48.731% |
| Pharming Group N.V. | 462.85 Million USD | -105.83% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -2363.009% |
| Avidity Biosciences, Inc. | 628.55 Million USD | -51.569% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -4934.392% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -4934.392% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -476.271% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -2003.677% |
| Acelyrin, Inc. | 742.69 Million USD | -28.276% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -14364.263% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -14778.838% |
| Summit Therapeutics Inc. | 202.94 Million USD | -369.424% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -1180.948% |
| Senti Biosciences, Inc. | 119.48 Million USD | -697.339% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -317.222% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -466.492% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -11429.614% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -19856.814% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | -103.049% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -670.456% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -246.498% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | -101.483% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -9327.927% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -344.133% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -84048.251% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | -130.207% |
| Immix Biopharma, Inc. | 19.92 Million USD | -4681.352% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -157.467% |
| MEI Pharma, Inc. | 41.37 Million USD | -2202.579% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -2839.863% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -179.547% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -712.704% |
| Fortress Biotech, Inc. | 167.52 Million USD | -468.683% |
| Precigen, Inc. | 151.04 Million USD | -530.742% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -2700.553% |
| AlloVir, Inc. | 190.79 Million USD | -399.325% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -153.072% |
| Fate Therapeutics, Inc. | 506.21 Million USD | -88.198% |
| ImmuCell Corporation | 43.8 Million USD | -2074.694% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | -46.722% |
| Onconetix, Inc. | 88.82 Million USD | -972.592% |
| PureTech Health plc | 693.97 Million USD | -37.281% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -875.269% |
| Elevation Oncology, Inc. | 89.09 Million USD | -969.347% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -15261.045% |
| Seer, Inc. | 436.26 Million USD | -118.373% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -1067.558% |
| Innoviva, Inc. | 1.24 Billion USD | 23.387% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -619.431% |
| ESSA Pharma Inc. | 149.12 Million USD | -538.867% |
| GlycoMimetics, Inc. | 45.31 Million USD | -2002.308% |
| GT Biopharma, Inc. | 14.1 Million USD | -6652.371% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -209.423% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -294.158% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | -101.881% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -1779.188% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -900.601% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -150740.738% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | -68.219% |
| Aptose Biosciences Inc. | 12.92 Million USD | -7272.325% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -4208.039% |
| Soligenix, Inc. | 9.79 Million USD | -9624.0% |
| Century Therapeutics, Inc. | 360.69 Million USD | -164.13% |
| Kura Oncology, Inc. | 448.93 Million USD | -112.212% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -250.063% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -5408.482% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -758.967% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -364.386% |
| Autolus Therapeutics plc | 375.38 Million USD | -153.793% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -278.599% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -168.225% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -1839.046% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | -44.1% |
| GRI Bio, Inc. | 2.95 Million USD | -32129.093% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -8883.231% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -458.714% |
| IGM Biosciences, Inc. | 423.41 Million USD | -125.004% |
| INmune Bio, Inc. | 57 Million USD | -1571.36% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -328.165% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -1034.951% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -3547.805% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -13740.84% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -1166.44% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -546.954% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -475.631% |
| Coherus BioSciences, Inc. | 629.6 Million USD | -51.316% |
| Verastem, Inc. | 149.71 Million USD | -536.324% |
| Abeona Therapeutics Inc. | 64 Million USD | -1388.535% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | -86.017% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -516.801% |
| Histogen Inc. | 19.07 Million USD | -4894.977% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -4106.113% |
| Surrozen, Inc. | 46.08 Million USD | -1967.474% |
| Organovo Holdings, Inc. | 6.34 Million USD | -14905.387% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -22011.302% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -561.469% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -7972.293% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -1165.733% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -11082.815% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -162.472% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -5165.122% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | -121.865% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -7454.021% |
| Apollomics, Inc. | 55.38 Million USD | -1620.064% |
| Amarin Corporation plc | 831.68 Million USD | -14.55% |
| Mesoblast Limited | 669.15 Million USD | -42.373% |
| Turnstone Biologics Corp. | 112.81 Million USD | -744.473% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | -65.467% |
| Synaptogenix, Inc. | 31.11 Million USD | -2961.973% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -7719.206% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | -73.829% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -16123.598% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -12870.339% |
| Exelixis, Inc. | 2.94 Billion USD | 67.621% |
| Better Therapeutics, Inc. | 22.94 Million USD | -4052.43% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -161.342% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | -20.788% |
| NLS Pharmaceutics AG | 1.84 Million USD | -51490.537% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -11840.54% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -6383.103% |
| Gritstone bio, Inc. | 177.76 Million USD | -435.916% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -898.838% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -5233.544% |
| Avid Bioservices, Inc. | 336.55 Million USD | -183.07% |
| Insmed Incorporated | 1.32 Billion USD | 28.36% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -9794.66% |
| MediWound Ltd. | 66.45 Million USD | -1333.503% |
| OmniAb, Inc. | 401.98 Million USD | -136.997% |
| Alector, Inc. | 621.82 Million USD | -53.209% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -165.67% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -17614.615% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -1580.47% |
| Zai Lab Limited | 1.03 Billion USD | 8.067% |
| Revance Therapeutics, Inc. | 478.45 Million USD | -99.119% |
| Aura Biosciences, Inc. | 255.07 Million USD | -273.495% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | -27.021% |
| Immunic, Inc. | 54.29 Million USD | -1654.53% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -257.854% |
| Veracyte, Inc. | 1.13 Billion USD | 16.27% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -7958.103% |
| FibroGen, Inc. | 423.52 Million USD | -124.941% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -27019.044% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -20013.393% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -17446.659% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 91.638% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -10719.898% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | -84.111% |
| TG Therapeutics, Inc. | 329.58 Million USD | -189.056% |
| Galecto, Inc. | 38.22 Million USD | -2392.197% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -3222.263% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 78.135% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -304.705% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -3735.005% |
| XBiotech Inc. | 227.24 Million USD | -319.239% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -898.838% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -568.087% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -233.207% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -645.053% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -149.396% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 36.104% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -161.125% |
| Vaxxinity, Inc. | 44.35 Million USD | -2047.976% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | -84.287% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -5019.432% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -212.307% |
| NexImmune, Inc. | 8.59 Million USD | -10985.614% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -8791.042% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -5462.388% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 97.12% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -4200.873% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -242769.489% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -449.644% |
| Ainos, Inc. | 31.84 Million USD | -2891.954% |
| Pluri Inc. | 39.52 Million USD | -2310.231% |
| Prothena Corporation plc | 696.38 Million USD | -36.806% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -237.098% |
| Celularity Inc. | 143.88 Million USD | -562.102% |
| Rallybio Corporation | 115.62 Million USD | -723.985% |
| Cue Biopharma, Inc. | 61.53 Million USD | -1448.337% |
| MeiraGTx Holdings plc | 458.16 Million USD | -107.935% |
| Omeros Corporation | 378.26 Million USD | -151.856% |
| Humacyte, Inc. | 128.22 Million USD | -642.996% |
| Immunocore Holdings plc | 597 Million USD | -59.58% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -2947.737% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -1290.182% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 9.203% |
| CalciMedica, Inc. | 12.18 Million USD | -7718.564% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -275.593% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -457.43% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -206.297% |
| Sana Biotechnology, Inc. | 565.29 Million USD | -68.529% |
| Pulmatrix, Inc. | 33.95 Million USD | -2705.501% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -3409.512% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -576.349% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 26.771% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -631.776% |
| Cytokinetics, Incorporated | 824.31 Million USD | -15.574% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -4410.212% |
| Nutriband Inc. | 7.51 Million USD | -12573.573% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -1106.642% |
| Vor Biopharma Inc. | 209.82 Million USD | -354.035% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 86.809% |
| Evogene Ltd. | 51.1 Million USD | -1764.331% |
| ProKidney Corp. | 420.55 Million USD | -126.534% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -1637.443% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -9906.977% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | -74.364% |
| CorMedix Inc. | 82.05 Million USD | -1060.971% |
| BioLineRx Ltd. | 63.92 Million USD | -1390.328% |
| Tango Therapeutics, Inc. | 402.56 Million USD | -136.654% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -3278.34% |
| Atai Life Sciences N.V. | 293.47 Million USD | -224.621% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -484.01% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -647.69% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | -69.51% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -885.01% |
| MediciNova, Inc. | 66.26 Million USD | -1337.592% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -983.245% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -21249.486% |
| GeoVax Labs, Inc. | 9.28 Million USD | -10162.518% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -61.957% |
| Biomea Fusion, Inc. | 199.92 Million USD | -376.52% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 49.942% |
| Mereo BioPharma Group plc | 66.49 Million USD | -1332.641% |
| Cullinan Oncology, Inc. | 485.09 Million USD | -96.392% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | -55.445% |
| Absci Corporation | 234.48 Million USD | -306.3% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -12923.814% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -180.293% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -477.102% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | -81.009% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -243.074% |
| Allakos Inc. | 243.61 Million USD | -291.073% |
| Imunon, Inc. | 21.91 Million USD | -4246.606% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -269.699% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -53.285% |
| BioAtla, Inc. | 119.65 Million USD | -696.179% |
| NLS Pharmaceutics AG | 1.84 Million USD | -51490.537% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -29486.708% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | -48.201% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -893.06% |
| XOMA Corporation | 234.3 Million USD | -306.61% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -330.624% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -657.042% |
| aTyr Pharma, Inc. | 122.06 Million USD | -680.466% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -519.021% |
| Akero Therapeutics, Inc. | 580.27 Million USD | -64.181% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | -94.259% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -762.407% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -6185.26% |
| Akari Therapeutics, Plc | 4.35 Million USD | -21775.821% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -5491.791% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 45.035% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -30791.58% |
| UroGen Pharma Ltd. | 178.31 Million USD | -434.287% |
| Sutro Biopharma, Inc. | 470.73 Million USD | -102.384% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -171335.358% |
| Orgenesis Inc. | 14.55 Million USD | -6446.811% |
| Entera Bio Ltd. | 11.76 Million USD | -7997.68% |
| GH Research PLC | 226.3 Million USD | -320.986% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -1641.858% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -786.753% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -12139.466% |
| Replimune Group, Inc. | 487.72 Million USD | -95.335% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -11703.76% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | -46.921% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -30791.58% |
| Portage Biotech Inc. | 7.77 Million USD | -12146.973% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -21249.486% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -244.0% |
| OncoCyte Corporation | 74.89 Million USD | -1172.088% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -46755.671% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -16363.639% |
| Purple Biotech Ltd. | 44.3 Million USD | -2050.449% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -2691.69% |
| scPharmaceuticals Inc. | 94.47 Million USD | -908.364% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -5179.547% |
| HilleVax, Inc. | 344.43 Million USD | -176.596% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -29896.599% |
| Tharimmune, Inc. | 10.94 Million USD | -8603.25% |
| Genprex, Inc. | 10.67 Million USD | -8828.202% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | -92.0% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -889.789% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -39170.074% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -22771.336% |
| OKYO Pharma Limited | 1.54 Million USD | -61712.383% |
| Savara Inc. | 177.56 Million USD | -436.534% |
| Curis, Inc. | 77.28 Million USD | -1132.748% |
| Daré Bioscience, Inc. | 21.28 Million USD | -4376.47% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -1389.773% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -11681.994% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -4818.135% |
| BeiGene, Ltd. | 5.8 Billion USD | 83.589% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -7728.844% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 54.386% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -166.152% |
| Erasca, Inc. | 395.29 Million USD | -141.007% |
| bluebird bio, Inc. | 619.16 Million USD | -53.868% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -21935.871% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 86.075% |
| DBV Technologies S.A. | 182.98 Million USD | -420.637% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -21935.871% |
| Moderna, Inc. | 18.42 Billion USD | 94.83% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -5129.687% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -8122.786% |
| Molecular Templates, Inc. | 35.38 Million USD | -2592.513% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -589.033% |
| Travere Therapeutics, Inc. | 788.91 Million USD | -20.76% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -213.638% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -816.526% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | -104.604% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -203.95% |
| MacroGenics, Inc. | 306.82 Million USD | -210.505% |
| RenovoRx, Inc. | 1.46 Million USD | -64885.812% |
| Adicet Bio, Inc. | 207.29 Million USD | -359.583% |
| Prime Medicine, Inc. | 193.85 Million USD | -391.456% |
| Aditxt, Inc. | 44.57 Million USD | -2037.119% |
| Adagene Inc. | 115.72 Million USD | -723.211% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -21288.675% |
| Quantum-Si incorporated | 298.25 Million USD | -219.427% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 35.951% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -12257.982% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -171.205% |
| SciSparc Ltd. | 11.18 Million USD | -8419.871% |
| Vericel Corporation | 353.65 Million USD | -169.383% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -7700.888% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -1574.309% |
| Generation Bio Co. | 374.75 Million USD | -154.215% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -274.095% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -500.814% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -179.083% |
| Invivyd, Inc. | 229.18 Million USD | -315.694% |
| Relay Therapeutics, Inc. | 843.98 Million USD | -12.881% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -7728.65% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -422.338% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -4564.571% |
| 2seventy bio, Inc. | 565.42 Million USD | -68.491% |
| ADMA Biologics, Inc. | 329.18 Million USD | -189.412% |
| Clene Inc. | 52.34 Million USD | -1720.164% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -1522.036% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -633.438% |
| GeoVax Labs, Inc. | 9.28 Million USD | -10162.518% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | -45.739% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -819.488% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -630.67% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -876.599% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -1241.876% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -292.777% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 51.395% |
| Evaxion Biotech A/S | 12.88 Million USD | -7291.731% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -277.962% |
| Verve Therapeutics, Inc. | 752.68 Million USD | -26.572% |
| Trevena, Inc. | 40.6 Million USD | -2246.243% |
| Surrozen, Inc. | 46.08 Million USD | -1967.474% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -321.812% |
| Cingulate Inc. | 3.49 Million USD | -27186.538% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -5629.1% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -1350.285% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -8053.38% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -254.798% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | -27.203% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -656.753% |
| Clearmind Medicine Inc. | 4.32 Million USD | -21930.673% |
| Kronos Bio, Inc. | 213.27 Million USD | -346.688% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -496.237% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -11028.786% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -158.539% |
| Statera Biopharma, Inc. | 21.16 Million USD | -4400.265% |
| ImmunityBio, Inc. | 504.45 Million USD | -88.857% |
| Korro Bio, Inc. | 221.66 Million USD | -329.793% |
| Kineta, Inc. | 10.28 Million USD | -9166.53% |
| BioVie Inc. | 25.2 Million USD | -3679.272% |
| Codexis, Inc. | 136.56 Million USD | -597.631% |
| Celularity Inc. | 143.88 Million USD | -562.102% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | -49.947% |
| Celcuity Inc. | 191.21 Million USD | -398.219% |
| Virax Biolabs Group Limited | 5.48 Million USD | -17272.308% |
| Cibus, Inc. | 544.41 Million USD | -74.995% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -656.741% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -4537.325% |
| IN8bio, Inc. | 33.7 Million USD | -2726.224% |
| Kodiak Sciences Inc. | 479.37 Million USD | -98.738% |
| Annexon, Inc. | 297.67 Million USD | -220.045% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -450.657% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -593.023% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -4438.141% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 68.138% |
| Eyenovia, Inc. | 28.77 Million USD | -3210.329% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -313.265% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -13087.874% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -1463.687% |
| Arcellx, Inc. | 825.13 Million USD | -15.459% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -1066.986% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | -106.088% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -2998.185% |
| Moolec Science SA | 24.05 Million USD | -3861.085% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -207.196% |
| Geron Corporation | 394.07 Million USD | -141.753% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -836.675% |
| Royalty Pharma plc | 16.38 Billion USD | 94.184% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | -60.125% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -13519.974% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -7821.069% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -321.433% |
| Humacyte, Inc. | 128.22 Million USD | -642.996% |
| Structure Therapeutics Inc. | 482.01 Million USD | -97.647% |
| 89bio, Inc. | 596.26 Million USD | -59.776% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -277.824% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -51396.865% |
| Genelux Corporation | 27.89 Million USD | -3315.524% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -965.615% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -315.245% |
| Notable Labs, Ltd. | 19.54 Million USD | -4775.349% |
| Liquidia Corporation | 120.43 Million USD | -691.069% |
| Mustang Bio, Inc. | 17.74 Million USD | -5269.699% |
| Immunovant, Inc. | 666.71 Million USD | -42.894% |
| Quantum-Si incorporated | 298.25 Million USD | -219.427% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -559.754% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -1659.032% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -442.702% |
| Acasti Pharma Inc. | 73.3 Million USD | -1199.716% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -20827.794% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -3547.805% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 1.255% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -18256.591% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -4081.959% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -1746.195% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -427.249% |
| PepGen Inc. | 143.05 Million USD | -565.976% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -2392.849% |
| United Therapeutics Corporation | 7.16 Billion USD | 86.707% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -4865.817% |
| Solid Biosciences Inc. | 164.93 Million USD | -477.603% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -16123.598% |
| Immuneering Corporation | 102.58 Million USD | -828.69% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -22011.302% |
| Silo Pharma, Inc. | 7.74 Million USD | -12198.924% |
| Belite Bio, Inc | 94.64 Million USD | -906.627% |
| XOMA Corporation | 234.3 Million USD | -306.61% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -308.551% |
| Bionomics Limited | 27.64 Million USD | -3345.654% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | -137.34% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -787.149% |
| uniQure N.V. | 831.68 Million USD | -14.549% |
| Cassava Sciences, Inc. | 151.66 Million USD | -528.164% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -21288.675% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -247.844% |
| Forte Biosciences, Inc. | 38.98 Million USD | -2344.053% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -23289.77% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -2486.658% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -13087.874% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -27019.044% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -7959.318% |
| Altimmune, Inc. | 210.64 Million USD | -352.284% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -22.473% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -787.149% |
| Compugen Ltd. | 121.33 Million USD | -685.181% |
| Peak Bio, Inc. | 2.59 Million USD | -36592.593% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -452.84% |
| Benitec Biopharma Inc. | 52.21 Million USD | -1724.731% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -178.68% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -2639.746% |
| Zura Bio Limited | 100.84 Million USD | -844.728% |
| PolyPid Ltd. | 15.37 Million USD | -6097.58% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -698.662% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -2639.746% |
| Instil Bio, Inc. | 325.63 Million USD | -192.569% |
| argenx SE | 4.54 Billion USD | 79.027% |
| Immunome, Inc. | 148.54 Million USD | -541.371% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -507.294% |
| Verona Pharma plc | 308.12 Million USD | -209.191% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -995.565% |
| Shattuck Labs, Inc. | 159.56 Million USD | -497.059% |
| CervoMed Inc. | 9.97 Million USD | -9453.171% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -405.525% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -8265.753% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -431.029% |
| Moolec Science SA | 24.05 Million USD | -3861.085% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -15473.275% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -450.866% |
| AnaptysBio, Inc. | 452.38 Million USD | -110.591% |
| Design Therapeutics, Inc. | 289.64 Million USD | -228.919% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -1208.194% |
| NeurAxis, Inc. | 509.49 Thousand USD | -186886.406% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -17483.832% |
| Lumos Pharma, Inc. | 40.63 Million USD | -2244.338% |
| Achilles Therapeutics plc | 161.45 Million USD | -490.063% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -995.565% |
| 180 Life Sciences Corp. | 5.25 Million USD | -18013.82% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -1252.722% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -11028.786% |
| Nutriband Inc. | 7.51 Million USD | -12573.573% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -274.065% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -378.017% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -1150.055% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -1544.955% |
| MoonLake Immunotherapeutics | 526.54 Million USD | -80.934% |
| Palisade Bio, Inc. | 14.05 Million USD | -6679.761% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -353.026% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 34.734% |
| Neurogene Inc. | 222.57 Million USD | -328.036% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | -47.334% |
| AEON Biopharma, Inc. | 6.84 Million USD | -13818.072% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | -110.291% |
| Sesen Bio, Inc. | 189.17 Million USD | -403.606% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -250.426% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -6847.936% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -22.085% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -256.822% |
| Athira Pharma, Inc. | 160.24 Million USD | -494.522% |
| Vaccinex, Inc. | 3.63 Million USD | -26137.731% |
| HCW Biologics Inc. | 28.51 Million USD | -3241.178% |
| XOMA Corporation | 234.3 Million USD | -306.61% |
| Nektar Therapeutics | 398.03 Million USD | -139.35% |
| Arvinas, Inc. | 1.3 Billion USD | 26.974% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -5491.791% |
| Merus N.V. | 458.49 Million USD | -107.787% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -366.17% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -428.674% |
| Rezolute, Inc. | 132.73 Million USD | -617.729% |
| Clene Inc. | 52.34 Million USD | -1720.164% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -6283.676% |
| BeyondSpring Inc. | 24.8 Million USD | -3740.261% |
| Synlogic, Inc. | 75.55 Million USD | -1161.009% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -7931.462% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -10073.985% |
| Peak Bio, Inc. | 2.59 Million USD | -36592.593% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -444.915% |
| Krystal Biotech, Inc. | 818.35 Million USD | -16.415% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -296.232% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | -31.263% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -26532.532% |
| MannKind Corporation | 475.19 Million USD | -100.483% |
| Ikena Oncology, Inc. | 192.09 Million USD | -395.956% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -7023.463% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -717.488% |
| Gossamer Bio, Inc. | 311.91 Million USD | -205.432% |
| CohBar, Inc. | 16.36 Million USD | -5721.284% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -2609.359% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -12923.814% |
| Legend Biotech Corporation | 1.84 Billion USD | 48.464% |
| Mural Oncology plc | 301.74 Million USD | -215.728% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -2952.033% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -16671.551% |
| Disc Medicine, Inc. | 367.99 Million USD | -158.887% |
| Champions Oncology, Inc. | 26.13 Million USD | -3545.691% |
| REGENXBIO Inc. | 573.97 Million USD | -65.983% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -35079.546% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -517.084% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -7789.41% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -180.175% |
| Vaxart, Inc. | 91.83 Million USD | -937.452% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -1490.368% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -542.292% |
| Cellectis S.A. | 334.27 Million USD | -185.007% |
| Longeveron Inc. | 12.17 Million USD | -7723.058% |
| Repare Therapeutics Inc. | 253.9 Million USD | -275.222% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 70.817% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -374.337% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 54.386% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -58527.2% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -243.052% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -484.122% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -586.655% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -3632.827% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 95.809% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 17.438% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -7700.888% |
| Veru Inc. | 50.59 Million USD | -1782.942% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -1991.392% |
| Cingulate Inc. | 3.49 Million USD | -27186.538% |
| Passage Bio, Inc. | 150.54 Million USD | -532.829% |
| Context Therapeutics Inc. | 16.06 Million USD | -5831.07% |
| Exicure, Inc. | 11.58 Million USD | -8127.047% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -153.343% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -489.384% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -5352.679% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -186.313% |
| Nuvalent, Inc. | 732.38 Million USD | -30.081% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -6275.047% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -963.818% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -6613.354% |
| OmniAb, Inc. | 401.98 Million USD | -136.997% |
| Anew Medical, Inc. | 19.45 Million USD | -4796.661% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -3464.59% |
| Lipocine Inc. | 23 Million USD | -4041.946% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -581.434% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -211.78% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -1034.951% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -683.851% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -11906.2% |
| Sage Therapeutics, Inc. | 882.27 Million USD | -7.981% |
| Ocugen, Inc. | 64.54 Million USD | -1375.966% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -664.963% |
| Q32 Bio Inc. | 306.11 Million USD | -211.216% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -22540.019% |
| Alumis Inc. Common Stock | 89.61 Million USD | -963.13% |
| Equillium, Inc. | 50.53 Million USD | -1785.399% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -1166.962% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -2208.24% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -55912.601% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -3544.436% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -1378.394% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -25461.125% |
| Dominari Holdings Inc. | 57.55 Million USD | -1555.186% |
| Edesa Biotech, Inc. | 8.89 Million USD | -10615.919% |
| vTv Therapeutics Inc. | 11.01 Million USD | -8546.687% |
| Bio-Techne Corporation | 2.81 Billion USD | 66.135% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -1.662% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | -17.406% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -243.108% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -2184.524% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | -42.707% |
| Nkarta, Inc. | 378.88 Million USD | -151.446% |
| BioCardia, Inc. | 2.98 Million USD | -31794.61% |
| Iterum Therapeutics plc | 26.25 Million USD | -3528.059% |